Morphic Therapeutic Revenue and Competitors
Estimated Revenue & Valuation
- Morphic Therapeutic's estimated annual revenue is currently $21.5M per year.
- Morphic Therapeutic received $80.0M in venture funding in September 2018.
- Morphic Therapeutic's estimated revenue per employee is $201,000
- Morphic Therapeutic's total funding is $134.5M.
Employee Data
- Morphic Therapeutic has 107 Employees.
- Morphic Therapeutic grew their employee count by 5% last year.
Morphic Therapeutic Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 347 | -5% | $634M | N/A |
#2 | $50.9M | 253 | N/A | N/A | N/A |
#3 | $39.6M | 197 | -12% | N/A | N/A |
#4 | $11.6M | 214 | 0% | $506.4M | N/A |
#5 | $4360M | 37257 | 175% | N/A | N/A |
#6 | $16.3M | 81 | N/A | N/A | N/A |
#7 | $37.2M | 185 | N/A | N/A | N/A |
#8 | $3.2M | 16 | N/A | N/A | N/A |
#9 | $5.6M | 28 | -3% | N/A | N/A |
#10 | $888.2M | 4419 | 0% | N/A | N/A |
What Is Morphic Therapeutic?
Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. Despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$134.5M
Total Funding
107
Number of Employees
$21.5M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Morphic Therapeutic News
“With compelling preclinical data across a number of programs, we are accelerating our advance into the clinic,” Morphic CEO Praveen Tipirneni said in a statement. Most human cells express integrins on the surface, but the proteins’ pathology contributes to a wide range of human diseases, inclu ...
Morphic Therapeutic, a Waltham, Mass.-based biotechnology company developing a new generation of oral integrin therapies, completed an $80m Series B financing. The round was co-led by Omega Funds and Novo Holdings with participation from Invus and EcoR1 Capital and Series A investors. In connec ...
Last month, Morphic closed an $80 million Series B financing – in which AbbVie Ventures participated – led by Omega Funds and Novo holdings, along with participation from new investors EcoR1 Capital and Invus. AbbVie had also taken part in the previous Series A funding round. Participants in the ...
Praveen Tipirneni, CEO of Morphic Therapeutic, certainly felt that way about his first chance to address colleAuges. But the offer also started a ...
Schrödinger secures further funding, extends collaboration with Morphic Therapeutic on computational discovery platform for oral integrin ...
Praveen Tipirneni, CEO of Waltham-based Morphic Therapeutic, is taking flack for a cartoon he drew about the biotech industry that bears a ...
Other Companies in Waltham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $16.6M | 107 | 3% | $125.4M |
#2 | $19.4M | 108 | -28% | N/A |
#3 | $29.2M | 108 | -5% | N/A |
#4 | $29.4M | 109 | -3% | N/A |
#5 | $36.3M | 110 | N/A | N/A |
Morphic Therapeutic Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2016-07-01 | $51.5M | A | SR One | Article |
| 2018-09-26 | $80.0M | B | Omega Funds | Article |
